As C-type lectin receptor, CD302 has roles in cell immune and migration (35, 36), and acts as a prognostic biomarker in myeloma (37), is also a potential therapeutic target for acute myeloid leukemia (38). Here, CLEC4D is linked to acute myeloid leukemia.